Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.

Karolina Piejko,Bożena Cybulska-Stopa,Marcin Ziętek,Robert Dziura,Łukasz Galus,Natasza Kempa-Kamińska,Barbara Ziółkowska,Ewa Rutkowska,Tomasz Kopciński,Tomasz Kubiatowski,Wiesław Bal,Rafał Suwiński,Jacek Mackiewicz,Grażyna Kamińska-Winciorek,Anna M Czarnecka,Piotr Rutkowski

Targeted oncology（2023）

引用 0|浏览15

暂无评分

摘要

We confirmed significant improvement in the mOS and mPFS of unresectable and/or metastatic BRAF mutated-melanoma patients treated outside clinical trials with V + C as compared with V, with no major increase in toxicity for the combination.

查看译文

关键词

cobimetinib therapy,vemurafenib,long-term,real-world,braf-mutated

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要